Brokers Issue Forecasts for PBH Q3 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities research analysts at DA Davidson issued their Q3 2025 earnings estimates for Prestige Consumer Healthcare in a research report issued on Monday, November 11th. DA Davidson analyst L. Weiser forecasts that the company will post earnings of $1.16 per share for the quarter. DA Davidson currently has a “Buy” rating and a $95.00 price target on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare’s FY2025 earnings at $4.46 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.07 EPS.

Separately, Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.20.

Prestige Consumer Healthcare Stock Up 1.7 %

NYSE:PBH opened at $81.75 on Tuesday. The stock’s 50 day moving average price is $72.55 and its two-hundred day moving average price is $69.84. The company has a quick ratio of 1.90, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $4.05 billion, a price-to-earnings ratio of 19.89, a price-to-earnings-growth ratio of 2.27 and a beta of 0.47. Prestige Consumer Healthcare has a twelve month low of $56.61 and a twelve month high of $82.00.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently modified their holdings of the business. Intech Investment Management LLC purchased a new stake in Prestige Consumer Healthcare in the third quarter valued at $620,000. Quest Partners LLC grew its holdings in Prestige Consumer Healthcare by 2,582.0% during the 3rd quarter. Quest Partners LLC now owns 11,774 shares of the company’s stock valued at $849,000 after purchasing an additional 11,335 shares in the last quarter. Natixis Advisors LLC grew its holdings in Prestige Consumer Healthcare by 11.4% during the 3rd quarter. Natixis Advisors LLC now owns 14,581 shares of the company’s stock worth $1,051,000 after acquiring an additional 1,491 shares in the last quarter. Huntington National Bank lifted its position in shares of Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after buying an additional 181 shares during the last quarter. Finally, MQS Management LLC bought a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at about $552,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.